Skip to content

Foot and Ankle Strengthening Program to Improve Physical Function in Menopausal Women (FAMEX)

Randomized Clinical Trial of the Effects of a 12-Week Foot and Ankle Strengthening Program on Physical Function and Quality of Life in Menopausal Women

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07472205
Acronym
(FAMEX)
Enrollment
70
Registered
2026-03-16
Start date
2026-09-01
Completion date
2027-01-31
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause, Musculoskeletal Function, Physical Function

Brief summary

This randomized controlled trial will evaluate the effects of a 12-week foot and ankle strengthening program on physical function and health-related quality of life in menopausal women. Menopause is associated with hormonal changes that may negatively affect muscle strength, balance, and functional capacity, potentially leading to reduced mobility and increased risk of falls. Although exercise interventions have demonstrated benefits in this population, most programs focus on global lower-limb training and rarely target the foot and ankle complex, which plays a key role in postural stability and gait propulsion. Approximately 60 menopausal women aged 45-65 years will be randomly assigned to either an intervention group performing a structured foot and ankle strengthening program or a control group maintaining their usual physical activity. The intervention will last 12 weeks and will include one supervised weekly session and four home-based sessions. The primary outcome will be ankle plantarflexion isometric strength measured by hand-held dynamometry. Secondary outcomes will include ankle strength in other directions, intrinsic foot muscle function, gait speed, spatiotemporal gait parameters, balance, foot-related functional status, and health-related quality of life.

Detailed description

Menopause represents a physiological transition characterized by a progressive decline in estrogen and other sex hormones. These hormonal changes influence musculoskeletal health and may lead to reductions in muscle strength, impaired neuromuscular control, decreased balance capacity, and increased risk of functional decline. Such alterations may negatively affect mobility and quality of life in midlife and older women. Exercise is widely recognized as an effective non-pharmacological strategy to mitigate the negative musculoskeletal consequences associated with menopause. Previous studies have demonstrated improvements in muscle strength, balance, gait speed, and overall physical function following exercise interventions in this population. However, most interventions focus on global lower limb training and rarely include specific exercises targeting the foot and ankle complex, despite its crucial role in postural control, propulsion during gait, and load distribution. This randomized controlled trial will evaluate the effectiveness of a structured foot and ankle strengthening program in menopausal women. The study will use a parallel two-group design with blinded outcome assessors and a 1:1 allocation ratio. Participants will be randomly assigned to either an intervention group or a control group. Approximately 60 women aged between 45 and 65 years who meet the clinical definition of menopause and have low to moderate physical activity levels will be recruited from the University of Málaga and the surrounding community. After baseline assessment, participants will be randomly allocated to the intervention or control group using a computer-generated randomization sequence with permuted blocks. The intervention will consist of a 12-week progressive exercise program specifically designed to strengthen intrinsic and extrinsic foot muscles, improve ankle function, enhance neuromuscular control, and promote functional capacity of the lower limb. Participants in the intervention group will perform one supervised weekly session at the University of Málaga and four home-based exercise sessions per week. The control group will maintain their usual physical activity without participating in the exercise program. Assessments will be conducted at baseline and after the 12-week intervention period by evaluators blinded to group allocation. Outcome measures will include isometric ankle strength measured by hand-held dynamometry, intrinsic foot muscle function tests, gait speed and spatiotemporal gait parameters measured using the OptoGait® system, balance performance assessed by the Single-Leg Stance Test, self-reported foot function using the Foot and Ankle Ability Measure (FAAM-ADL), and health-related quality of life measured with the EuroQol-5D questionnaire. The findings of this trial will contribute to understanding the role of targeted distal strengthening interventions in improving functional capacity and mobility in menopausal women and may support the development of clinically applicable exercise programs for this population

Interventions

OTHERFoot and ankle exercise program

A structured exercise program focused on strengthening intrinsic and extrinsic foot muscles, ankle stabilizers, and improving balance and functional performance. The program will be performed over a 12-week period.

Sponsors

University of Malaga
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Outcome assessors will be blinded to group allocation. Participants will be instructed not to disclose their group assignment during the assessment sessions.

Intervention model description

Participants will be randomly assigned in a 1:1 ratio to either a structured foot and ankle exercise program or a control group maintaining their usual physical activity. The intervention will last 12 weeks and outcomes will be assessed before and after the intervention period.

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Women aged between 45 and 65 years. * Postmenopausal status defined as at least 12 consecutive months of amenorrhea. * Low or moderate physical activity level assessed using the International Physical Activity Questionnaire (IPAQ). * Ability to understand study instructions and complete questionnaires in Spanish. * Willingness to participate in the study and sign informed consent.

Exclusion criteria

* Neurological disorders affecting gait or motor control. * Lower limb surgery within the previous 6 months. * Active painful pathology of the foot or ankle that could interfere with the intervention or measurements. * Cognitive impairment limiting understanding or execution of the protocol. * Current participation in specific foot or ankle strengthening programs. * Habitual vigorous physical activity or participation in structured lower limb strength training programs within the previous three months.

Design outcomes

Primary

MeasureTime frameDescription
Isometric plantarflexion strength of the ankleBaseline and 12 weeksMaximal isometric plantarflexion strength of the ankle measured using hand-held dynamometry. Participants will perform maximal voluntary contractions in a standardized seated position with the knee flexed at 90° and the ankle in neutral position. Two trials of 3-5 seconds will be performed and the highest value will be recorded. Strength will be expressed in kilograms (Kg).

Secondary

MeasureTime frameDescription
Isometric ankle strength in dorsiflexion, inversion and eversionBaseline and 12 weeksMaximal isometric strength of ankle dorsiflexors, invertors and evertors measured using hand-held dynamometry under standardized conditions. Two maximal contractions will be performed for each movement and the highest value will be recorded.
Intrinsic foot muscle strength and functionBaseline and 12 weeksIntrinsic foot muscle function assessed through a standardized battery including toe flexor strength, the paper grip test, navicular drop test and the single-leg heel raise test. These tests evaluate the functional capacity and endurance of intrinsic foot muscles.
Walking speedBaseline and 12 weeksWalking speed assessed on a treadmill under two conditions: comfortable walking speed and maximal safe walking speed. Participants will walk for 60 seconds and the final velocity will be recorded in meters per second (m/s).
Spatiotemporal gait parametersBaseline and 12 weeksSpatiotemporal gait parameters including step length, stride length, cadence and stance time measured using the OptoGait system (Microgate, Bolzano, Italy).
Static balanceBaseline and 12 weeksStatic balance assessed using the Single Leg Stance Test. Participants will stand on one leg with eyes open and the maximum time maintaining balance will be recorded.
Change in dynamic balance assessed with the modified Star Excursion Balance Test (mSEBT)Baseline and 12 weeksDynamic balance will be assessed using the modified Star Excursion Balance Test (mSEBT), performed in three reach directions: anterior, posteromedial, and posterolateral. Participants will maintain single-leg stance while reaching as far as possible with the contralateral limb in each direction. Reach distance will be recorded and normalized to limb length using the formula: normalized reach distance (%) = reach distance / limb length × 100. A composite score will also be calculated as: \[(anterior + posteromedial + posterolateral reach distances) / (3 × limb length)\] × 100. Higher normalized and composite scores indicate better dynamic balance performance.
Foot and ankle functional statusBaseline and 12 weeksSelf-reported foot and ankle function assessed using the Foot and Ankle Ability Measure \- Activities of Daily Living subscale (FAAM-ADL). Scores are expressed as a percentage from 0 to 100%, where higher scores indicate better function.
Health-related quality of lifeBaseline and 12 weeksHealth-related quality of life assessed using the EuroQol-5D questionnaire, including the EQ-5D index and the EQ-VAS scale.

Countries

Spain

Contacts

CONTACTJorge García Medina
jorgegarcia98@uma.es+34 684 10 52 97
CONTACTAna Marchena Rodríguez, PhD
amarchena@uma.es+34 951953488

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026